Skip to main content

Table 2 Application of drugs during follow-up

From: Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban

Medicine

Fondaparinux (n = 422)

Enoxaparin (n = 453)

P

Aspirin [n(%)]

419(99.3)

452(99.8)

0.567

Clopidogrel [n(%)]

338(80.1)

341(75.3)

0.088

ACE inhibitor or ARB [n(%)]

353(83.6)

379(83.7)

0.995

Calcium-channel blocker [n(%)]

69(16.4)

72(15.9)

0.854

Beta-blocker [n(%)]

360(85.3)

398(87.9)

0.268

Statin [n(%)]

397(94.0)

425(93.8)

0.874

  1. P < 0.05 was considered to indicate statistical significance